Genocea to Present at Two September Investor Conferences
August 29 2018 - 8:05AM
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing neoantigen cancer vaccines, today announced that
Chip Clark, president and chief executive officer, will present a
corporate overview at two upcoming investor conferences:
- Baird Global Healthcare Conference - 2018
- Wednesday, September 5, 2018 at 1:25pm PM ET in New York, New
York
- H.C. Wainwright 20th Annual Global Investment
Conference
- Thursday, September 6, 2018 at 11:40am AM ET in New York, New
York
The live webcasts of both presentations can be accessed by
visiting the "Events and Presentations" tab of the investor
relations section of the Genocea website at http://ir.genocea.com.
Replays of the webcasts will be archived for 90 days following the
conferences.
About Genocea Biosciences, Inc.Genocea's
mission is to help conquer cancer by designing and delivering
targeted cancer vaccines and immunotherapies. While traditional
immunotherapy discovery methods have largely used predictive
methods to propose T cell targets, or antigens, Genocea has
developed ATLAS™, its proprietary technology platform, to identify
clinically relevant antigens of T cells based on actual human
immune responses. Genocea is currently studying the safety,
immunogenicity, and efficacy of its lead neoantigen cancer vaccine,
GEN-009, in a Phase 1/2a clinical trial. For more information,
please visit www.genocea.com.
Contact: Jennifer LaVin
617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024